EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anemoside B4 mitigates cyclophosphamide-induced myelosuppression via preserving the bone marrow microenvironment

Jingyu Liu, Qinqin Wang, Xinghua Ni, Qian Su, Yujie Ning, Xiaoyun Xie, Jinying He, Shilin Yang, Renyikun Yuan, Hongwei Gao

Clinical Traditional Medicine and Pharmacology · 2025-09 · 6 (3) · 200237

DOI: 10.1016/j.ctmp.2025.200237 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Traditional Medicine and Pharmacology, 2025-09. Verfasst von Jingyu Liu und 9 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cyclophosphamide (CTX) induces myelosuppression, a dose-limiting adverse effect, through direct cytotoxicity to hematopoietic cells and disruption of the stromal microenvironment. Anemoside B4 (AB4), a saponin derived from Pulsatilla chinensis , exhibits antioxidant, anti-apoptotic, anti-inflammatory, and immunomodulatory activities; however, its role in protecting bone marrow from CTX-induced injury remains unknown. To investigate the potential of AB4 to mitigate CTX-induced myelosuppression and its underlying mechanisms using C57BL/6J mice. A CTX-induced myelosuppression model was established, with 40 mice randomly assigned to 5 groups ( n = 8 per group): Control, CTX alone, low-dose AB4 (AB4-L), high-dose AB4 (AB4-H), and granulocyte colony-stimulating factor (G-CSF, positive control). After 7 days of treatment, the following parameters were assessed: peripheral blood cell counts, spleen and thymus indices, bone marrow histology, levels of cytokines (granulocyte-macrophage colony-stimulating factor (GM-CSF), G-CSF, interleukin-6 (IL-6), interleukin-1 beta (IL-1β)). Flow cytometric analysis (bone marrow mesenchymal stem cells (BMSCs)), reactive oxygen species (ROS), cell cycle, apoptosis), molecular assays (superoxide dismutase (SOD), malondialdehyde (MDA)), terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL), and western blotting for γ-H2AX, p53, etc.) were also performed. Both doses of AB4 significantly increased red blood cell (RBC) and white blood cell (WBC) counts and elevated the thymus index ( P < 0.05). AB4 normalized hemosiderin deposition and megakaryocyte numbers, reduced the spleen index ( P < 0.01), increased levels of hematopoietic cytokines and BMSCs ( P < 0.01), decreased ROS and MDA levels, restored SOD activity, downregulated the expression of γ-H2AX, p53, BAX, and cleaved caspase-3/9 ( P < 0.01), and alleviated cell cycle arrest and apoptosis ( P < 0.01). AB4 mitigates CTX-induced myelosuppression by preserving the bone marrow microenvironment, reducing oxidative stress and DNA damage, relieving cell cycle arrest, and suppressing apoptosis. These findings suggest AB4 holds promise for alleviating chemotherapy-related hematotoxicity.

Zitieren

APA

Liu, J., Wang, Q., Ni, X., Su, Q., Ning, Y., Xie, X., He, J., Yang, S., Yuan, R., & Gao, H. (2025). Anemoside B4 mitigates cyclophosphamide-induced myelosuppression via preserving the bone marrow microenvironment. Clinical Traditional Medicine and Pharmacology, 6(3), 200237. https://doi.org/10.1016/j.ctmp.2025.200237

Vancouver

Liu J, Wang Q, Ni X, Su Q, Ning Y, Xie X, et al. Anemoside B4 mitigates cyclophosphamide-induced myelosuppression via preserving the bone marrow microenvironment. Clinical Traditional Medicine and Pharmacology. 2025;6(3):200237. doi:10.1016/j.ctmp.2025.200237

BibTeX
@article{Liu2025,
  author = {Liu, Jingyu and Wang, Qinqin and Ni, Xinghua and Su, Qian and Ning, Yujie and Xie, Xiaoyun and He, Jinying and Yang, Shilin and Yuan, Renyikun and Gao, Hongwei},
  title = {Anemoside B4 mitigates cyclophosphamide-induced myelosuppression via preserving the bone marrow microenvironment},
  journal = {Clinical Traditional Medicine and Pharmacology},
  year = {2025},
  volume = {6},
  number = {3},
  pages = {200237},
  doi = {10.1016/j.ctmp.2025.200237}
}
Kostenlos starten →